Activities per year
Activities
- 12 results
Search results
-
Vitreoretinal disease
Jackson, T. (Speaker)
20 May 2025Activity: Talk or presentation › Oral presentation
-
Role of VEGF-C and D inhibition in AMD
Jackson, T. (Invited speaker)
20 Sept 2024Activity: Talk or presentation › Oral presentation
-
Stereotactic radiotherapy for neovascular age-related macular degeneration (STAR): a pivotal, randomised, double-masked, sham-controlled device trial
Jackson, T. (Invited speaker)
19 Sept 2024Activity: Talk or presentation › Oral presentation
-
VEGF-A/-C/-D inhibition with sozinibercept and ranibizumab combination therapy for nAMD: subgroup analysis of a phase 2b study to assess the angiographic predictors of response
Jackson, T. (Speaker)
19 Sept 2024Activity: Talk or presentation › Oral presentation
-
Stereotactic radiotherapy for neovascular age-related macular degeneration (STAR): a pivotal, randomised, double-masked, sham-controlled device trial
Jackson, T. (Speaker)
15 Sept 2024Activity: Talk or presentation › Oral presentation
-
Results of Part A of KALAHARI, a Phase 2 Trial of THR-149, a plasma kallikrein inhibitor, for the treatment of diabetic macular oedema
Jackson, T. (Speaker)
2 Sept 2022Activity: Talk or presentation › Oral presentation
-
Designing, executing and interpreting randomised clinical trials
Jackson, T. (Invited speaker)
2 Sept 2022Activity: Talk or presentation › Oral presentation
-
Designing, executing and interpreting randomized clinical trials
Jackson, T. (Speaker)
2 Oct 2020Activity: Talk or presentation › Oral presentation
-
Vitrectomy, subretinal TPA and gas for submacular haemorrhage due to wet AMD
Jackson, T. (Keynote speaker)
14 Feb 2020Activity: Talk or presentation › Oral presentation
-
A multicentre, randomised, double-masked, sham controlled study of intravitreal OPT-302 in combination with ranibizumab, for wet AMD
Jackson, T. (Speaker)
15 Sept 2019Activity: Talk or presentation › Oral presentation
-
OPT-302 Phase 2b study in wet AMD: A multicentre, randomised, double-masked, sham controlled study of intravitreal OPT-302 in combination with ranibizumab, in participants with wet AMD
Jackson, T. (Speaker)
5 Sept 2019Activity: Talk or presentation › Oral presentation
-
INTREPID year 3 safety results
Jackson, T. (Speaker)
27 Jun 2018Activity: Talk or presentation › Oral presentation